- Home
- / Checkpoint Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Checkpoint Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$3.8
2024-10-29
Market Capitalization
$170.2 M
2024-10-29
Revenue
$41 K
FY, 2024
CreditSafe Score
?
Score changed on Jun 13, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 103.0K | 41.0K | |||||||
| General and administrative expense | 4.5M | 5.4M | 6.6M | 7.2M | 7.9M | 8.5M | 8.7M | 8.7M | 20.1M |
| Operating expense total | 24.7M | 24.5M | 40.2M | 26.6M | 24.3M | 57.0M | 58.5M | 56.2M | |
| EBIT | (22.2M) | (22.8M) | (36.7M) | (24.8M) | (23.2M) | (56.7M) | (58.3M) | (52.1M) | (56.2M) |
| EBIT margin, % | -137009.8% | ||||||||
| Interest income | 47.0K | 98.0K | 148.0K | 136.0K | 120.0K | 53.0K | 160.0K | 84.0K | 11.0K |
| Interest expense | 344.0K | ||||||||
| Net Income | (22.5M) | (22.7M) | (36.4M) | (24.7M) | (23.1M) | (56.7M) | (62.6M) | (51.8M) | (56.2M) |
| EPS | (7.1) | (3.0) | (1.4) |